| Serial Number | 79421230 |
| Word Mark | HIRUNDO |
| Filing Date | Monday, December 2, 2024 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Wednesday, January 7, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, January 27, 2026 |
| Goods and Services | Pharmaceutical preparations and substances in the field of gynecology and women's health, endometriosis, noninflammatory disorders of female genital tract, inflammatory diseases of female pelvic organs, disorders of breast, breast cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, fallopian tube cancer, polycystic ovarian syndrome, neoplasm of uncertain or unknown behaviour of the uterus and ovary, menopause, infertility, urinary tract, contraception, uterine fibroids and postprocedural pelvic peritoneal adhesions; medicinal preparations for the treatment and prevention of hormonal dysfunction and menopausal symptoms, conditions and disorders, endometriosis, noninflammatory disorders of female genital tract, inflammatory diseases of female pelvic organs, disorders of breast, breast cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, fallopian tube cancer, polycystic ovarian syndrome, neoplasm of uncertain or unknown behaviour of the uterus and ovary, menopause, infertility, urinary tract, contraception, uterine fibroids and postprocedural pelvic peritoneal adhesions; medicines for the treatment and prevention of hormonal dysfunction and menopausal symptoms, conditions and disorders, endometriosis, noninflammatory disorders of female genital tract, inflammatory diseases of female pelvic organs, disorders of breast, breast cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, fallopian tube cancer, polycystic ovarian syndrome, neoplasm of uncertain or unknown behaviour of the uterus and ovary, menopause, infertility, urinary tract, contraception, uterine fibroids and postprocedural pelvic peritoneal adhesions; biochemical medicines for the treatment and prevention of hormonal dysfunction and menopausal symptoms, conditions and disorders, endometriosis, noninflammatory disorders of female genital tract, inflammatory diseases of female pelvic organs, disorders of breast, breast cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, fallopian tube cancer, polycystic ovarian syndrome, neoplasm of uncertain or unknown behaviour of the uterus and ovary, menopause, infertility, urinary tract, contraception, uterine fibroids and postprocedural pelvic peritoneal adhesions; pharmaceutical preparations for the treatment and prevention of hormonal dysfunction and menopausal symptoms, conditions and disorders, endometriosis, noninflammatory disorders of female genital tract, Inflammatory diseases of female pelvic organs, disorders of breast, breast cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, fallopian tube cancer, polycystic ovarian syndrome, neoplasm of uncertain or unknown behaviour of the uterus and ovary, menopause, infertility, urinary tract, contraception, uterine fibroids and postprocedural pelvic peritoneal adhesions for use in the field of gynecology and female health; estrogen preparations for therapeutic purposes; pharmaceutical preparations containing estrogen for the treatment and prevention of hormonal dysfunction and menopausal symptoms, conditions and disorders, endometriosis, noninflammatory disorders of female genital tract, inflammatory diseases of female pelvic organs, disorders of breast, breast cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, fallopian tube cancer, polycystic ovarian syndrome, neoplasm of uncertain or unknown behaviour of the uterus and ovary, menopause, infertility, urinary tract, contraception, uterine fibroids and postprocedural pelvic peritoneal adhesions; pharmaceutical preparations for the treatment of female hormonal dysfunction; pharmaceutical preparations for use in hormone replacement therapy; pharmaceutical preparations for the treatment of menopausal symptoms, conditions and disorders |
| Goods and Services | Chemicals for industrial purposes and chemical preparations for scientific purposes; chemical reagents for scientific purposes in the field of molecular biology; bacterial preparations other than for medical or veterinary use; enzymes and enzyme preparations for industrial use; chemical preparations for analyses in laboratories for scientific use, other than for medical or veterinary purposes; biochemical preparations for scientific purposes; Chemical substances for analyses in laboratories, other than for medical or veterinary purposes, for use in the research and development and production of drugs, medicinal and pharmaceutical preparations; chemical additives for use in the manufacturing of pharmaceuticals |
| Goods and Services | Medical services; providing medical advice in the field of efficacy of pharmaceuticals; provision of medical data relating to the use of pharmaceuticals; medical information online and on the internet relating to products, solutions and pharmaceutical and medical advances; medical information online and on the internet about products, solutions, pharmaceutical or medical advances; providing medical research information in the field of pharmaceuticals |
| Goods and Services | Market research and business analysis services; business marketing consulting services in the field of pharmaceutical, biotechnology, biochemical, medical device and diagnostics industries; market analysis; providing business information and data processing services in the field of pharmaceutical, biotechnology, biochemical medical device, and diagnostics industries; compilation of statistics for business or commercial purposes in the field of biochemical medical devices |
| Goods and Services | Scientific, clinical surgery, medical and life-science research; research and development in the field of biotechnology and biochemistry; research and development in the field of pharmaceuticals, biopharmaceuticals, medical devices, and medical diagnostics; research relating to molecular sciences; research and development in the field of drug development; testing, analysis, and evaluation of pharmaceutical and biochemical products, especially for use in medicines; research and development of medicines; testing of pharmaceuticals; biotechnology research and development services; product development involving pharmaceutical products; medical and scientific research, namely, conducting clinical trials as part of the research and development of pharmaceuticals and medicines; clinical research in the field of production of chemicals for pharmaceutical use, pharmaceuticals, medical devices and medical diagnostics; scientific research, namely, providing analysis of statistical data in the field of biotechnology; scientific research, namely, providing analysis of statistical data in the field of biotechnological diagnostics industries |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, April 10, 2025 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, April 10, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 035 - Advertising; business management; business administration; office functions. |
| US Class Codes | 100, 101, 102 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, April 10, 2025 |
| Primary Code | 035 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, April 10, 2025 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, April 10, 2025 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | B.C.I. Pharma |
| Party Type | 11 - New Owner Before Publication |
| Legal Entity Type | 99 - Other |
| Address | BE |
| Party Name | Daphne Vervaet |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 98 - Unknown |
| Address | BE |
| Event Date | Event Description |
| Thursday, April 10, 2025 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, April 11, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, April 11, 2025 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, May 21, 2025 | ASSIGNED TO EXAMINER |
| Wednesday, May 21, 2025 | NON-FINAL ACTION WRITTEN |
| Thursday, May 22, 2025 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Friday, May 30, 2025 | CHANGE OF OWNER RECEIVED FROM IB |
| Monday, July 14, 2025 | REFUSAL PROCESSED BY MPU |
| Monday, July 14, 2025 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Saturday, August 2, 2025 | REFUSAL PROCESSED BY IB |
| Tuesday, December 30, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, December 30, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, December 30, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, January 2, 2026 | FINAL REFUSAL WRITTEN |
| Friday, January 2, 2026 | FINAL REFUSAL E-MAILED |
| Friday, January 2, 2026 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Friday, January 2, 2026 | EXAMINERS AMENDMENT -WRITTEN |
| Friday, January 2, 2026 | EXAMINERS AMENDMENT E-MAILED |
| Friday, January 2, 2026 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Friday, January 2, 2026 | EXAMINER'S AMENDMENT ENTERED |
| Friday, January 2, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, January 2, 2026 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Friday, January 2, 2026 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Friday, January 2, 2026 | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
| Friday, January 2, 2026 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |